Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Morning! Today, we have a deep probe into Moderna’s travails from STAT’s tireless Jason Mast. Also, a pharma bidding war, thoughts on psychedelic regulation, and the Trump administartion is trying to fast-track cheaper biosimilars.
The need-to-know this morning
-
A new drug-sales king has been crowned. Eli Lilly’s diabetes and weight-loss drug tirzepatide, marketed under the Mounjaro and Zepbound brand names, delivered $10.1 billion in third-quarter sales. Tirzepatide’s quarterly sales surpassed the $8.1 billion in sales from Merck’s cancer immunotherapy blockbuster Keytruda for the first time.
- More earnings from Bristol Myers Squibb, Biogen, Insmed, Apellis, and Astellas.
Moderna’s mRNA empire stumbles amid politics, retrenchment
Once seemingly on top of the world, Moderna now faces a brutal reset.
Continue to STAT+ to read the full story…
STAT Pharma: The science and business of new drug development
Leave a Reply